TBLON

BASELINE ASSESSMENT TOOL

PRO	PROFILE				
1.	Date	DD/ MM/YY			
2.	Province				
3.	District				
4.	Facility Name				
5.	Facility type	Public			
	(Tick all options that apply)	Private			
		Diagnostic			
		Treatment			
		Hospital			
		Clinic			
		Health post			
		MDR/RR TB initiating facility			
		MDR/RR DOT facility			
6.	Geo coordinates				
7.	SmartCare code				
8.	Distance from DHO				
9.	Catchment population (2022)				

HUMAN RESOURCE CAPACITY FOR TB SERVICE PROVISION						
	IAN RESOURCE AT THE FACILITY	NUMBER	COMMENT			
10.	Medical Doctors					
11.	Medical Licentiates					
12.	Clinical Officers					
13.	Nurses					
14.	Pharmacy personnel					
15.	Laboratory personnel					
16.	Environmental Health Technologist					
17.	Data clerks/associates					
18.	Nutritionist					
19.	Social workers					
20.	General workers					
21.	Community HCWs					
22.	Psychosocial counselor					
23.	Other					
TRAI	NINGS AND ORIENTATIONS	NUMBER TRAINED	POSITIONS OF STAFF TRAINED/ORIENTED			
24.	Adult TB training					
25.	Pediatric TB training					
26.	MDR TB training					
27.	Community Health workers training					
28.	Orientation/training on radiological diagnosis of TB					
29.	Orientation/ training in Drug surveillance and monitoring					
30.	Orientation/training in active TB case finding					
31.	Orientation/training in TB infection control					

32.	Orientation/training in TB preventive therapy	
33.	Laboratory TB Training	

	TB/ ART SERVICES	AVAILA	BILITY	
34.	TB/ ART Integration- One stop TB/HIV clinic	[Y]	[N]	
	Infection Control Measures in place			
35.	An infection control committee in place	[Y]	[N]	
36.	A written site – specific infection control (IC) plan in	[Y]	[N]	
	place			
37.	Designated sputum collection area	[Y]	[N]	
38.	Open waiting space	[Y]	[N]	
39.	Average waiting time for diagnosed TB patients at the TB clinic		•	
40.	Is health education conducted daily at the TB clinic	[Y]	[N]	
41.	If not, how often is health education provided	[0] never	[14]	
41.	ij not, now ojten is nealth education provided			
		[1] monthly		
		[2] every 2 weeks		
		[3] weekly		
		[4] every 2-4 days		
42.	Are the topics for health education documented	[Y]	[N]	
43.	If yes, what areas are covered at least every week-refer	Adherence to treatme	nt	
	to records on health education(tick all that apply)			
		disposal		
		Contact tracing		
		Diet		
		Keeping windows oper		
		Reporting of adverse e	effects	
		Other (specify)		
44.	Is health education on TB symptoms and early health	OPD		
	seeking behavior provided at other departments (tick all	ART		
	that apply)	MCH Nutrition		
		Other		
45.	If yes, on average, how frequently is health education	1] monthly		
45.	provided to all the departments TB	[2] every 2 weeks		
		[3] weekly		
		[4] every 2-4 days		
46.	Are MDR TB patients separated from drug susceptible	[Y]	[N]	
	TB patients			
47.	If yes, how are they separated	They are seen in differ	ent clinic areas	
		They are seen at differ the day	ent hours of	
		They are seen on different days		
		Other (specify)		

48.	TB/HIV coordinating body in place (minutes of	[Y]	[N]
	meetings)		

ENA	BLERS FOR SERVICE PROVISION (indicate	e either Yes or N	lo, and recor	d Quantities where Yes is ticked)
		AVAILA	BILITY	Quantity
MED	ICAL SUPPLIES			
49.	Weighing scale	[Y]	[N]	
50.	BP Machine	[Y]	[N]	
51.	Stethoscope	[Y]	[N]	
52.	Pulse oximeter	[Y]	[N]	
53.	Thermometer	[Y]	[N]	
54.	Phone	[Y]	[N]	
55.	Filling Cabinets	[Y]	[N]	
56.	Cooler boxes	[Y]	[N]	
57.	Specimen bags	[Y]	[N]	
58.	Consistent supply chain for sputum bottles	[Y]	[N]	
59.	Consistent supply chain for sharps boxes	[Y]	[N]	
60.	Consistent supply chain for gloves	[Y]	[N]	
61.	Face masks	[Y]	[N]	
62.	N95 respirators	[Y]	[N]	
63.	Handwashing equipment	[Y]	[N]	
64.	Stadiometers	[Y]	[N]	
65.	Hand wash soap	[Y]	[N]	
NTP	GUIDELINES			
66.	Childhood TB	[Y]	[N]	
67.	TB manual	[Y]	[N]	
68.	MDR TB	[Y]	[N]	
69.	Consolidated TB guidelines	[Y]	[N]	
70.	Consolidate National HIV treatment and prevention guidelines	[Y]	[N]	
71.	TPT	[Y]	[N]	
72.	TB infection control	[Y]	[N]	
JOB	AIDS		•	
73.	Childhood TB	[Y]	[N]	
74.	Adult TB	[Y]	[N]	
75.	MDR TB	[Y]	[N]	
76.	TPT	[Y]	[N]	
77.	TB infection control	[Y]	[N]	
78.	TB/COVID	[Y]	[N]	
79.	TB/HIV	[Y]	[N]	
IEC N	MATERIALS			
80.	Childhood TB	[Y]	[N]	
81.	Adult TB	[Y]	[N]	

82.	TB/HIV	[Y]	[N]	
83.	MDR TB	[Y]	[N]	
84.	TPT	[Y]	[N]	
85.	TB infection control	[Y]	[N]	
86.	TB/COVID	[Y]	[N]	

Α	Electronic patient record/SmartCare Assessment	Response		Comments
87.	Does this facility have SmartCare?	[Y]	[N]	
88.	If No to question 82: Any reasons why SmartCare is not in use?	Not yet Deploy Not Working Staff not Trains	Reason Smartcare isn't working	
89.	If Yes to question 82: Is the deployed SmartCare at the facility in eFirst or eLast?	E-First E-Last		
90.	Is SmartCare being used in the TB clinic?	[Y]	[N]	
91.	If Yes to question 85: Is it being used in elast or efirst mode	E-First E-Last		
92.	If Yes to question 85: Are there sufficient computers in the TB clinic?	[Y]	[N]	
93.	If Yes to question 85: Who primarily enters the data?	Data Associate Clinician Treatment Sup Volunteer Nurse Other	porter	
94.	If No to question 85: Any reason why?	Not yet Deploy Not Working Staff not Traine		Reason Smartcare isn't working
95.	Are the SmartCare computers using the latest version of SmartCare? (to specify the version)	[Y]	[N]	
96.	Do they have anti-virus software on them that is up to date?	[Y]	[N]	
97.	What kind of network do the computers connect to?	WIFI Wired LAN		
98.	Are the computers connected to a power backup system?	Solar UPS Inverter w/o So Generator	blar	

99.	Are the staff at the site trained in the use of SmartCare?	[Y]	[N]	
100.	If Yes: How many?	1		
101.	If No: How many staff need training in SmartCare			
102.	Are there any staff trained in SmartCare troubleshooting	[Y]	[N]	
103.	Does this facility have YATHU?	[Y]	[N]	
104.	Does this facility have any other patient data recording system?	[Y]	[N]	
В	M&E Processes			
	Are the following data sources are available?			Quantity
105.	Presumptive TB register	[Y]	[N]	
106.	Community Presumptive TB register	[Y]	[N]	
107.	Contact tracing forms	[Y]	[N]	
108.	Contact tracing register	[Y]	[N]	
109.	TPT register	[Y]	[N]	
110.	TB treatment cards	[Y]	[N]	
111.	TB ID cards	[Y]	[N]	
112.	TB treatment register	[Y]	[N]	
113.	Request for bacteriological examination of sputum	[Y]	[N]	
114.	Request form for culture and DST	[Y]	[N]	
115.	TB laboratory register	[Y]	[N]	
116.	MDR TB treatment card	[Y]	[N]	
117.	MDR TB treatment register	[Y]	[N]	
118.	Culture sample/results register	[Y]	[N]	
119.	TB appointment register	[Y]	[N]	
120.	Transfer forms	[Y]	[N]	
121.	Mortality audit forms (TB death review forms)	[Y]	[N]	
122.	Do you have any other registers apart from the ones listed here?	[Y]	[N]	
123.	Who is responsible for recording data in the register/data sources?	Data Associate Clinician Nurses Volunteer/TS Other		
	What challenges are there when recording data in the			
124.	registers/ data sources?			
		Data Associate	Щ	
		Clinician		
		Nurses		
		Volunteer		
125	Who is represented for constitue the result of	Other		
125.	Who is responsible for compiling the reports?	Data Assasiate		
		Data Associate		
		Clinician		
	Who is ween smile for an include a second of the first of	Nurses		
126	Who is responsible for reviewing aggregate data before its	Volunteer		
126.	submitted?	Other Data Associate		
127.	Who is responsible for submitting the reports?	Data Associate In-charge		
	1 1	10-		<u> </u>

		Clinician Nurses Volunteer Other	
128.	Can you provide templates of reports?	[Y]	[N]
129.	Are all the TB relevant staff trained in HMIS?	[Y]	[N]
130.	How do you ensure that the numbers entered are accurate and complete?		
С	Site has updated guidelines for reporting printed and easily accessible for reference		
131.	Does the site have printed copies of the most updated indicator guidance maintained by the designated facility staff member?	[Y]	[N]
132.	Does the site have a comprehensive list of fiscal year targets posted and visible at TB Department? If yes, document facility target on TB notification	[Y]	[N]
133.	Does the site have job-aids of indicator definitions posted and visible at TB department?	[Y]	[N]
134.	Does the site have the posted SOPs on steps for aggregating and reporting monthly and quarterly indicators?	[Y]	[N]
D	Site conducts data review on a regular basis		
	Does the facility conduct data reviews on a regular basis prior to reporting?	[Y]	[N]
135.	Is there documentation of these data reviews (i.e., meeting minutes)? (VISUALLY VERIFY)	[Y]	[N]
136.	Do facility staff and IP-staff participate in the development of data presentations for monthly and quarterly site-level data review meetings?	[Y]	[N]
137.	Are action plans developed and revisited during these meetings? (VISUALLY VERIFY)	[Y]	[N]
138.	Does the site reconcile monthly results across different data aggregation tools (i.e., between Registers, SmartCare MER and HIA2 reports)?	[Y]	[N]
139.	Is there documented evidence of reconciliation available at the clinic (e.g., meeting minutes, results of cross-checks, etc)?	[Y]	[N]
140.	Is there evidence of TB data use at facility level in the past 12 months (existence of graphs, charts or periodic data review reports)?	[Y]	[N]
141.	Does the facility conduct TB mortality reviews (TB death reviews)?	[Y]	[N]
142.	If yes to Q141, how often is it done	Monthly Quarterly	
143.	If yes to Q141 how is it done?		

LAB D	LAB DIAGNOSTIC SERVICES						
LAB E	LAB EQUIPMENT AND SUPPLIES (Skip this section if not diagnostic facility)						
144.	144. GeneXpert [Y] [N] Microscopy						

145.	No of modules	Skip if not Xpert	on site	Fluorescent Microscope	[Y]	[N]
146.	No of functional modules			ZN microscope	[Y]	[N]
147.	What type of laboratory information system being used for TB in the laboratory?	[1] DISA [2] eLabs [3] Other, specify Skip if not available on site				
148.	Does DISA transmit TB results electronically to clinicians?	Skip if not available on site				
149.	Does eLabs transmit TB results electronically to clinicians?	Skip if not available on site				
150.	Internet connectivity	[Y]	[N]			
151.	Does the facility use TB LAMP?	[Y]	[N]			
152.	Does the facility use TB LAM?	[Y]	[N]			
153.	Is the Back-up power solution available?	[Y]	[N]	[Y]	1]	N]
154.	Date of last EQA for smear microscopy	DD/MM/YY	/ΥΥ	DD	/MM/YYYY	
155.	State the results of last smear microscopy EQA					
156.	Date of the last proficiency testing for GeneXpert	DD/MM/YY	ΥY			
157.	State the results of last GeneXpert proficiency testing (EQA)					
158.	Consistent supply of cartridges	[Y]	[N]	Consistent supply of microscopy reagents	[Y]	[N]
159.	If no, when was the last stock out?					
160.	How long did it last?					
161.	What was the cause of the stock out?	[1] laboratory did an order [2] laboratory platorder late [3] poor quantificathe laboratory [4] order placed; store supplied learequested [5] order placed, supply from distrance [6] Reagents expire	district ss than		[1] laboratory an order [2] laboratory order late [3] poor quant the laboratory [4] order place store supplied requested [5] order place from district state [6] Reagents ex	placed an cification by ed; district less than ed, no supply tore

COUR	IER SYSTEM							
162.	What is the frequency of facility?	courier system at the	[0] Never[1] Quarterly[2] Monthly[3] Weekly[4] twice a week[5] Daily[6]Call on demand					
163.	Is the TB courier system in programs? (e.g. HIV)	ntegrated with other	[Yes] [No]				
164.	Which institution is support district courier system?	orting the current intra	1] PHO [2] DHO [3] Facility [4] IP, specify:					
165.	Are the courier system pa materials available?	ckaging, transportation	[Yes] [No]					
166.	What is the average turna for sample courier? (Rand results)							
167.	Have you ever sent to sen laboratories?	d a sample to the culture	[Y]	[N]				
168.	If yes, how easy is it (was sample transported to the		[1] Very easy [2] Easy [3] Difficult [4] Very difficult	·				
169.	How is(was) the sample so laboratory? (tick all that apply)	ent to the culture	[1] Through the province[2] Through the district[3] Through partners[4] Using public means					
170.	On average, how long doe receive the results?	es it (did it) take you to	[0] Results were not received [1] 2-3 months [2] 3-4 months					
171.	If diagnostic center, how samples for processing?	many facilities send						

	RADIOLOGY	(X-RAY) SERVICES					
172.	Does your facility have an X-ray machine?	[Y]	[N]				
173.	If yes what type of machine is available	analogue	digital				
174.	Is the X-ray machine functional	[Y]	[N]				
175.	Is there someone who knows how to read	A radiologist					
	the obtained radiographic images? (tick)	A radiographer					
		A radiology technologist					
		A trained clinician (medical officer,					
		clinical officer, nurse, other)					
176.	If there is no one able to read/interpret the	Radiographs transmitted electronically					
	radiographic images, what happens then?	to a radiologist or other experienced					
	(tick)	reader at a remote site					
		Radiographs physically transmitted to a					
		radiologist or other experienced reader					
		at a remote site					

		Other (specify)	
177.	Do you use any artificial intelligent system to interpret the images (e.g CAD4TB)	[Y]	[N]
178.	How frequent do you experience breakdown	weekly	
	/machine does not work in a month	Every two weeks	
		One in a month	
179.	Do patient pay for X-ray services?	[Y]	[N]
180.	If patient pay, how much?	Less than K50	
		K50	
		K100	
		More Than K100	
181.	If no X-ray machine, how far is the place with		
	X-Ray services		
182.	If patient pay, how much?	Less than K50	
		K50	
		K100	
		More Than K100	

	PUBLIC PRIVATE PARTNERSHIP	AVAIL	ABILITY		
	Public facility only				
183.	Does the facility receive any referrals from private facilities to evaluate	[Y]	[N]		
	patients for TB?				
184.	If yes to Q183, which facilities do you usually receive referrals from(name				
	them)				
185.	If yes to Q183, does the facility provide feedback to the referring private	[Y]	[N]		
	facility when patient is received? (check evidence of feedback)				
186.	Does the TB treatment register have any TB cases whose entry point is private	[Y]	[N]		
	facility				
187.	If yes TO Q186, how many				
	Private facility only				
188.	Does the facility refer any patients to public facilities?	[Y]	[N]		
189.	If yes to Q188, what are the commonest reason for referral (tick all that apply)	Sputum examination			
		Chest x-ray			
		To start treatment			
		Complications of TB			
190.	If yes to Q188, which facility do you usually refer patients to		T		
191.	Do you usually receive feedback from the site you refer patients to?	[Y]	[N]		
192.	Do you sometimes receive referrals for treatment from other private facilities?	[Y]	[N]		
193.	If yes, what are the commonest reasons or referral (tick all that apply)	Sputum exa	mination		
		Chest x-ray			
		To start trea			
		Complications of TB			
194.	What is the cost of x-ray at this facility (indicate not applicable if facility has no				
	chest x-ray)				
195.	What is the cost of a GeneXpert at this facility(indicate not applicable if facility				
	has no GeneXpert)				

196.	What is the cost of microscopy at this facility(indicate not applicable if facility			
	doesn't offer TB microscopy)			
197.	What is the cost of TB treatment at this facility(indicate not applicable if facility			
	doesn't provide TB treatment)			
198.	Does the facility receive any Xpert cartridges from the Ministry of Health	[Y]	[N]	[N /A]
	(indicate not applicable if facility has no GeneXpert)			
199.	Does the facility receive any microscopy reagents from the Ministry of Health	[Y]	[N]	[N /A]
	(indicate not applicable if facility does not offer TB microscopy)			
200.	Does the facility receive anti-TB drugs from the Ministry of Health (indicate	[Y]	[N]	[N /A]
	not applicable if facility doesn't provide TB treatment)			

	DINIESS FOR DECENTRALISATION OF MDR TB SERVICES (includes	AVAILABILITY				
ques	tions not covered in other sections)					
	Skip this section if the facility is not a hospital					
201.	Does the facility have an isolation ward	[Y]	[N]			
202.	If yes to Q201, how many beds are in the isolation ward?					
203.	Does the facility has specialized treatment for chronic disease conditions (tick all that apply)	[1] Hyperte				
		[3] Respiratory conditions [4] other (specify)				
204.	What monitoring tests for TB and TB/HIV treatment is the facility able to provide (Tick all that apply)	[1] Chest x- [2] Full Bloo [3] Liver fur [4] Renal fu tests and el [5] Thyroid tests [6] CD4 cou [7] Viral loa	ray od count nction tests nction ectrolytes function			
205.	Does the facility have sufficient waiting area for TB patients	[Y]	[N]			
206.	Does the facility have sufficient additional space for storage of DR-TB drugs	[Y]	[N]			
207.	Does the facility have electronic DR-TB register	[Y]	[N]			
208.	If yes, is anyone trained on the electronic DR-TB register	[Y]	[N]			

	COMMUNITY ENGAGEMENT	AVAILABILITY				
209.	Does the facility conduct any TB community outreach activities?	[Y]	[N]			
210.	If yes to Q209, outline the activities	ТВ				
		sensitization/He				
		alth education				
		Contact Tracing				
		Defaulter tracing				
		Follow up of				
		patients				
		(monitoring)				

		visit support	
		groups/meetings	
		Other (specify)	
		Other (specify)	
211.	If yes to Q, who funds the TB community outreach activities?	MoH	
		CHAZ	
		MoH/GF	
		JSI	
		Right to Care	
		CITAM+	
		AFYA	
		Jhiego	
		Other (specify)	
212.	Does the facility organize periodic community TB stakeholder's	[Y]	[N]
	meetings?		
213.	If yes to Q4, how frequently?	[1] Monthly	
	, 35 15 🔾 1, 11511 1154451111, 1	[2] Quarterly	
		[3] Every six month	ıs
		[4] Once a year	.5
214.	Does the facility have Community Based Volunteers that conduct	[Y]	[N]
211.	Community Based TB Care activities attached to TB department?	[]	[]
215.	How many community-based volunteers selected or engaged, if	Nil	
213.	any?	1	
	uny:	2	
		3	
		4	
		5	
		<5	
216	Dans the facility have an active waighback and health as we with a	[Y]	[N]
216.	Does the facility have an active neighborhood health committee		[N]
217.	What role does the NHC play on the TB program/activities	Community	
		sensitization	
		Monitoring of	
		treatment	
		Compilation and	
		submission of	
		community	
		reports	
		Identification and	
		referral of	
		presumptive	
0.15		Contact tracing	[N]
218.	Have the CBVs received any capacity building training?	[Y]	[N]
219.	If yes to previous question, when were they last trained?	This year	
		Last year	
		Two years ago	
		More than two	
		years	
220.	Who trained them?	Facility	
		DHO	
		MoH/GF	
		ETB	

		CITAM+	
		CHAZ	
		AFYA	
		Jhpiego	
		Other (specify)	
221.	How long was the training?	1 day	
		2 days	
		3 days	
		5 days	
		More than 5 days	
222.	What modules or training curriculum was used?	MoH TS modules	
		WHO modules	
		Other (specify)	
		Not sure	
223.	What are some of the TB activities CBVs conduct at the facility	Community	
	and in the community?	sensitization	
		Monitoring of	
		treatment	
		Compilation and	
		submission of	
		community	
		reports	
		Identification and	
		referral of	
		presumptive	
		Contact tracing	
		Other (specify)	
224.	How are CBVs assigned tasks and distributed in your facility	ART	
	, , , , , , , , , , , , , , , , , , , ,	TB clinic	
		OPD	
		MCH	
		IPD	
		Registry	
		Other (specify)	
	What tools are available to CBVs to account/ document their	Community	
	contribution to the activities?	presumptive	
	contribution to the activities:	registers	
		Community	
		referral forms	
		Community CBV	
		reports	
		CBV monthly report	
		TB treatment register	
225	De Community Valuntanus mundures and a state of the community of	Other (specify)	[N]
225.	Do Community Volunteers produce any activity reports?	[Y]	[N]
226.	Do Community Volunteers receive stipends or any other	[Y]	[N]
20-	incentives?	f v 1	f a i 3
227.	Are there any community-based groups of former TB patients?	[Y]	[N]
228.		CHAZ	

	What other partners support Community TB in your	MoH/GF	
	facility/district	JSI	
	raciiity/district		
		Right to Care	
		CITAM+	
		AFYA	
		Jhiego	
		Other (specify)	
229.		Nill	
230.	In your district are there any existing partnerships with community radio stations to air health Programmes?	[Y]	[N]
231.	How many community radio stations do you have in your	Nil	
	district?	1	
		2	
		3	
		4	
		5	
		<5	
232.	What are some of the issues prevailing in your catchment that	Distance	
_52.	hinder people from accessing TB services at facilities	Culture beliefs	
	Times. People from decessing 15 services at facilities	Gender	
		HCW attitude	
222	And the wear on existing increase (at improvement) and the same desired	Other (specify)	
233.	Are there specific issues (stigma, myths and misconceptions,	Stigma	
	occupational routines and social issues) concerning men and	Myths	
	women that hinder their access to TB services. Please itemize.	Misconceptions	
		Occupational	
		Routines	
		Social	
		Other (specify)	
234.	What support structures exist in your catchment for TB patients	Nil	
		Private hospital	
		Chemistry/pharm	
		асу	
		Treatment both	
		NHC	
		TB support group	
		Treatment	
		supporters/CBVs	
		Other (specify)	
235.	Are there any active community nutritional support groups within your catchment area or district?	[Y]	[N]
236.	What kind of livelihood and income generating activities that	Public services	
	exist in your community	Mining	
	, ,	Fishing	
		Farming	
		Other (specify)	
227	How do CDVs portisinate in these patients in the second	Other (specify)	
237.	How do CBVs participate in these activities to support them	Nil	
	financially?	Public services	
		Mining	

		Fishing			
		Farming			
		Other (specify)			
238.	Are there any congregate settings in your community/district that exposes people to the risk of TB	[Y]	[N]		
239.	What are some of the specific behaviors can you share that	Nil			
	increase the risk to TB in your community	Overcrowding			
		Mining			
		Smoking			
		beer drinking			
		Other (specify)			
		Other (specify)			
240.	What are some of the challenges do you experience in your	Nil			
	community that affect your implementation of community TB	Traditional			
	activities.	healers			
		Churches			
		Social			
		Traditional			
		leaders			
		distance			
		Few CBVs			
		Other (specify)			

				В	Baselin	e Perfo	rmance	e Trend	Analys	sis							
			20	21		Jan	anuary -March 2022 April -			April -Ju	ne 202	22	July - September 2022)22	
		F 15+	M 15+	F <15	M <15	F 15+	M 15+	F <15	M <15	F 15+	M 15+	F <15	M <15	F 15+	M 15+	F <15	M <15
ТВ Са	se Detection														ı		
241.	Facility attendance																
242.	Presumptive TB cases																
243.	TB sample submitted																
244.	TB Samples tested with Xpert																
245.	TB Samples tested with microscopy																
246.	TB Samples tested with Urine LAM																
247.	Number diagnosed with TB																
248.	Started on ATT																
тв/ні	V					ı	ı	I	1		1	ı		I			1
249.	Total notifications																
250.	Number started on Treatment(Bact+Clinica Ily diagnosed)																
251.	Number with documented HIV status																
252.	HIV positive																
253.	No of HIV positive with ART start date																

TREA	TREATMENT OUTCOMES											
	Period of Enrolment	Number enrolled on	Treatment success		Died		Treatment failed		Loss to follow-up		Unevaluated	
		treatment	F	М	F	М	F	М	F	М	F	М
254.	2020											
255.	Q1 (Jan – Mar) 2021											
256.	Q2(Apr -Jun) 2021											
257.	Q3(Jul – Sep) 2021											

INDICA	TORS	2021	January - March 2022	April -June 2022	July - September 2022
DR TB S	SURVEILLANCE				
258.	No of high risk for DR-TB (retreatment cases, smear positive at month 2 and after, develop TB after TPT, presumptive TB patients who contacts to DR-TB)				
259.	Number of high-risk for DR-TB cases with access to Xpert (with Xpert results documented)				
260.	Number of High-risk for DR-TB with evidence of request for culture/ DST (samples sent for culture and DST)				
261.	Number of High-risk for DR-TB cases with Culture/DST results				
CONTA	ACT TRACING				
262.	Bacteriologically confirmed TB cases				
263.	Households screened for TB				
264.	Presumptive TB cases				
265.	Presumptive TB cases that submitted sample for evaluation				
266.	Diagnosed with TB				
267.	Started on ATT				
268.	Under 5 contacts initiated on TPT				

202))	MDR/RR TB PATIENT CARE (skip Q196-202)) if facility is not an MDR TB initiating Centre		2021 M<15 F<1 M> F>1			2022				April to June 2022			July - Sep 2022			COMMENT		
Centr			F<1 5	M> 15	F>1 5	M< 15	F<1 5	M >1 5	F>1 5	M< 15	F< 15	M> 15	F> 15	M<1 5	F<1 5	M> 15	F>15	
269.	No of MDR/RR TB patients detected at a facility																	
270.	No of MDR/RR TB patients started on treatment at a facility																	
271.	No of MDR/RR patients started on standardized oral longer treatment regimen																	
272.	No of MDR/RR patients started on standardized oral shorter treatment regimen																	
273.	No of MDR/RR patients started on individualized treatment regimen																	
274.	No of XDR TB patients																	
275.	Number contact traced																	
276.	No of patients on treatment with baseline DST																	
277.	Number of patients on treatment with up to date culture results (2 months before current date)																	
278.	Number of patients with documented adverse drug safety monitoring and management																	
	MDR Outcomes	MDR/RR- TB patient who Started treatment in 2018		who Started treatment in 2019			MDR/RR- TB patient who Started 2020 (Jan to Mar, Apr – Jun)			MDR/RR- TB patient who Started 2020 (Jul to Sep)								
		M<15	F<1 5	M> 15	F>1 5	M< 15	F<1 5	M >1 5	F>1 5	M< 15	F< 15	M> 15	F> 15	M<1 5	F<1 5	M> 15	F>15	
279.	No. of Patients enrolled on DR TB Treatment																	

280.	No of patients who completed treatment/cured (Treatment success)								
281.	Number of patients who died								
282.	No. of patients attending their semi-annual post treatment reviews								

Laboratory Indicators (Skip section if facility is not a diagnostic site)		2021	January to March 2022	April to June 2022	July - Sep 2022	COM MENT	2021	Jan to Marc h 2022	April to June 2022	July - Sep 2022	COM MENT
					Microscopy						
283.	Number of TB samples received										
284.	Number of TB samples processed										
285.	TB detected										
286.	Rifampicin resistance detected										
287.	Average Turnaround time (Days)										

	WASTE MANAGEMENT AND ENVIRONMENTAL RISK	ASSEN	1ENT	
	Staff	AVAIL	ABILITY	COMMENT
288.	Have health care workers at the TB clinic been trained on waste management?	[Y]	[N]	If yes, how many have been trained
289.	Which kind of waste is generated in relation to TB service provision	[3] sha [4] che	ectious irps emicals	itical waste
290.	Quantity of general waste produced/day (estimated, kg)			
291.	Quantity of infectious waste produced/day (estimated, kg)			
292.	Number of sharps boxes used/ day			
293.	Quantity of chemical waste produced/day (estimated, kg)			
294.	Quantity of pharmaceutical waste produced/day (estimated, kg)			
295.	Into which categories are medical waste separated? (tick all those that apply)	[1] ger [2] info [3] sha [4] cho	ectious irps emicals	ition itical waste
296.	Proper segregation of waste is:	[1] bad 2] insu [3] sat [4] god	ifficient isfactory	1
297.	safe handling of waste is:	[0] noi [1] ba	n-exister d (low) ufficient	nt

		T	
		[3] satisfactory	
		[4] good	
		[5] excellent (high	
298.	what kind of specific containers do you use?	[0] no specific co	ntainer;
		[1] plastic	
		[2] metallic	
		[3] cardboard	
		[4] bag	
		[5] box	
		[6] other	
299.	For what reasons are there shortages, if any?	[0] no shortages	
		[1] budget	
		[2] logistical	
		[3] other (specify	7)
300.	Do you have a specific color-coding system?	Υ	N
301.	Is infectious waste container are lidded?	Υ	N
302.	Do you have a specific area for medical waste storage?	Υ	N
303.	Is the area only accessible for authorized persons.	Υ	N
304.	Are different kind of waste stored in separated storage	Υ	N
	areas?		
305.	Is hazardous and non-hazardous waste collected and	Υ	N
	transported separately?		
306.	What kind of means do you use?	[0] open device	
		[1] closed device	
		[2] other (specify	·)
307.	Do you think current practices offer enough security?	Υ	N
308.		[0] the HCF	
		[1] municipal ser	vice
	who generally transports the medical waste?	[2] private compa	
	5 , ,		, ,
309.	which kind of system is used for waste treatment?	[0] none	
	,	[1] open fire	
		[2] incinerator	
		[3] chem. Disinf	
		[4] other	
310.	What is the current capacity of the waste treatment	[.] 0 0	
310.	system(s) in kg/day?		
	system(s) in kg/ uay:		
311.	How often treatment is done per week		
312.	Any operation problems of the waste treatment	[0] none	
312.		[1] money	
	system; if so for what reasons?	-	
		2] maintenance	
		[3] spare parts	
		[4] other	

313.	What do you do when it doesn't function?			
314.		[0] on-site		
	Is the waste disposal system on or off-site?	[1] off-site		
315.		[0] none		
		[1] open dump		
		[2] sanitary landfill		
		[3] small burial pit	t	
	which kind of disposal site is used for the HCW?	[4] other		
316.	Is the disposal area secured?	Υ	N	

Curr	ent partner s	upport			
	Partner	Area of support (tick all areas of support)	Require of addit support	ional	Specify additional support required
317.		[1] Strengthening TB lab services	Υ	N	
		[2] Facility TB case finding	Υ	N	
		[3] Community TB case finding	Υ	N	
		[4] Increasing MDR TB case detection	Υ	N	
		[5] improving MDR TB treatment outcomes	Υ	N	
		[6] Public private partnership	Υ	N	
		[7] Improved use of data for decision making including roll out of TB module for SmartCare	Y	N	
318.		[1] Strengthening TB lab services	Υ	N	
		[2] Facility TB case finding	Υ	N	
		[3] Community TB case finding	Υ	N	
		[4] Increasing MDR TB case detection	Υ	N	
		[5] improving MDR TB treatment outcomes	Υ	N	
		[6] Public private partnership	Υ	N	
		[7] Improved use of data for decision making including roll			
		out of TB module for SmartCare	Υ	N	
319.		[1] Strengthening TB lab services	Υ	N	
		[2] Facility TB case finding	Υ	N	
		[3] Community TB case finding	Υ	N	
		[4] Increasing MDR TB case detection	Υ	N	
		[5] improving MDR TB treatment outcomes	Υ	N	
		[6] Public private partnership	Υ	N	
		[7] Improved use of data for decision making including roll out of TB module for SmartCare	Y	N	
320.		[1] Strengthening TB lab services	Υ	N	
		[2] Facility TB case finding	Υ	N	
		[3] Community TB case finding	Υ	N	
		[4] Increasing MDR TB case detection	Υ	N	
		[5] improving MDR TB treatment outcomes	Y	N	
		[6] Public private partnership	Υ	N	1
		[7] Improved use of data for decision making including roll out of TB module for SmartCare	Y	N	

Facility staff Name:	Position:	Data	
Assessed By:	Position	Date:	
COMMENTS			